0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Solutions for Influenza Vaccine Development

Evolution of Influenza Vaccine Substrates

The 1930s marked the development of cultivating influenza viruses in embryonated eggs. This method dominant until the 1950s. The discovery of influenza virus growth in various cell lines (MDCK and Vero cells) in the late 1950s led to a gradual shift from embryonated eggs to cells-based vaccine production.

Evolution of Influenza Vaccine Substrates
Evolution of influenza vaccine substrates from embryonated eggs to cells.
Reviews in Medical Virology

Solutions for Enhanced Influenza Vaccine Development

Antigens for WHO's Recommended Influenza Vaccine Strains

Antigens for WHO's
Recommended Influenza
Vaccine Strains

Antigens for WHO's
Recommended Influenza
Vaccine Strains

• Encompassing the WHO's Latest Recommended Influenza Strains
• Validated Natural HA Trimer
• Validated Natural NA Tetramer

Solutions for Vaccine Antigen Quantification and Quality Control

Solutions for Vaccine
Antigen Quantification and
Quality Control

Solutions for Vaccine
Antigen Quantification and
Quality Control

• HA & NA Specific Antibodies
• Antibody Pair & Method Development Services

Personalized Drug Screening

Vaccine Potency
Assessment Tools
and Services

Vaccine Potency
Assessment Tools
and Services

• Humoral Immunity Assessment Methods Development Service (ELISA)
• Cellular Immune Assessment Kit (ELISpot)

Antigens for WHO's Recommended Influenza Vaccine Strains

Influenza’s constant antigenic drift necessitates annual vaccine reformulation for optimal efficacy. the WHO updates the formulation of the vaccine annually to ensure the vaccine match the seasonal circulating viruses. To support Influenza vaccine research and development, ACROBiosystems has developed key reagents consistent with influenza vaccine components recommended by WHO.

Antigens Encompassing the WHO's Latest Recommended Influenza Strain

Flu Season WHO's Recommended Influenza
Vaccine Strains
Subtypes Hemagglutinin (HA) Neuraminidase (NA)
2024-2025 A/Wisconsin/67/2022 H1N1 HA1-V52H7 NEE-V524m
A/Victoria/4897/2022 H1N1 HA1-V52H8 NEE-V524c
A/Thailand/8/2022 H3N2 H32-V52H3 NEE-V524w
A/Massachusetts/18/2022H3N2H32-V52H3NEE-V524v
B/Austria/1359417/2021B/VictoriaHAE-V52H3NEE-V5245
B/Phuket/3073/2013B/YamagataHAE-V52H4NEE-V5246
Others A/Wisconsin/588/2019 H1N1 HA1-V52H3 NEE-V524k
A/Victoria/2570/2019H1N1HA1-V52H6NEE-V524e
A/Sydney/5/2021H1N1HA1-V52H4NEE-V5248
A/Georgia/12/2022H1N1HAE-V52H7NEE-V524p
A/Sydney/1304/2022H3N2HA2-V52H9NE2-V5247
A/Darwin/6/2021H3N2HA2-V52H5NEE-V5247
A/Darwin/9/2021 H3N2 HA2-V52H6 / HA2-V82E6 NE2-V5249
A/Bangkok/1/1979H3N2HA2-V52H3 /
A/Hong Kong/483/97H5N1HA1-V5229 /
A/Vietnam/1194/2004H5N1HA1-V52H9 /
A/Thailand/1(KAN-1)/2004H5N1 / HA1-V5245
A /Guangdong/18SF020H5N6HA6-V52H3NEE-V524h
A/turkey/Germany-MV/R2472/2014H5N8HA8-V52H3NEE-V5249
A/Shanghai/2/2013 H7N9 HA9-V5253 / HA9-V52H3 /
A/guinea fowl/Hong Kong/WF10/99 H9N2 HA1-V52H5 / HA2-V52H7 /
B/Singapore/WUH4618/2021B/VictoriaHAE-V52H6NEE-V524u
B/Singapore/INFTT-16-0610/2016B/YamagataHAE-V52H5NEE-V524r

Natural HA Trimer Assay Data

High Homogeneity

Natural HA Trimer Assay Data

The purity of Influenza A [Victoria/4897/2022] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H8) is more than 90% and the molecular weight of this protein is around 220-265 kDa verified by SEC-MALS.

High Bioactivity (ELISA & SPR)

Natural HA Trimer Assay Data

Immobilized Influenza A [Victoria/4897/2022] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H8) at 1 μg/mL (100 μL/well) can bind Human Anti-HA (H1N1) antibody3E1 with a linear range of 1-31.25 ng/mL (QC tested).

Natural HA Trimer Assay Data

Human Anti-HA (H1N1) antibody3E1 captured on Protein A Chip can bind Influenza A [Victoria/4897/2022] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H8) with an affinity constant of 4.64 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Hemagglutination Activity

Natural HA Trimer Assay Data

Influenza B virus [Austria/1359417/2021 (B/Victoria lineage)] Hemagglutinin (HA) Protein, His Tag (Cat. No. HAE-V52H8) binding to RBCs (Rooster red blood cells) at a final concentration of 0.4688 μg/mL can lead to complete hemagglutination. The final concentration of the sample in the first well was 15 μg/mL.

Natural NA Tetramer Assay Data

High Homogeneity

Cardiac

The purity of Influenza A (A/Sydney/1304/2022) Neuraminidase (NA) Protein, His Tag (Cat. No. NE2-V5247) is more than 90% and the molecular weight of this protein is around 50-70 kDa verified by SEC-MALS.

High Bioactivity (ELISA )

Cardiac

Immobilized Influenza A (A/Sydney/1304/2022) Neuraminidase (NA) Protein, His Tag (Cat. No. NE2-V5247) at 1 μg/mL (100 μL/well) can bind Anti-NA(A/PAN) Antibody,Mouse IgG with a linear range of 4-63 ng/mL (QC tested).

Solutions for Vaccine Antigen Quantification and Quality Control

The assurance of vaccine potency is important for the timely release and distribution of influenza vaccines. Antigen quantification and quality control are important steps in evaluating vaccine effectiveness. ACROBiosystems provides key reagents for Influenza vaccine antigen quantification and quality control.

HA Antibodies & Customization Service

Cross-reactivity of HA antibodies against HA proteins of varying influenza strains by ELISA.

Cross-reactivity of HA antibodies against HA proteins of varying influenza strains by ELISA

Click to view the details for HA antibodies

Vaccine Potency Assessment Tools and Services

Potency assessment plays a crucial role in the development of influenza vaccines. It serves as a critical tool to evaluate the effectiveness and consistency of vaccine formulations. By potency testing ensures that vaccines meet regulatory standards for safety and efficacy. ACROBiosystems provides key reagents & service for Influenza vaccine potency assessment.

Cellular lmmune Assessment Kit (ELISpot)

Species Cytokines Cat.No.
ELISpot Kit Mouse Interferon-γ (IFN-γ) RAS-SP002
TNF-alpha RAS-SP004
IL-2 RAS-SP006
Human Interferon-γ (IFN-γ) RAS-SP001
TNF-alpha RAS-SP003

Humoral lmmunity Assessment Methods Development Service (ELISA)

Inquire About Our Solutions

ACRO Quality

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje